Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Sep 1;17(9):e0273408.
doi: 10.1371/journal.pone.0273408. eCollection 2022.

Comparison of baseline lymphoma and HIV characteristics in Malawi before and after implementation of universal antiretroviral therapy

Affiliations
Observational Study

Comparison of baseline lymphoma and HIV characteristics in Malawi before and after implementation of universal antiretroviral therapy

Yolanda Gondwe et al. PLoS One. .

Abstract

Access to antiretroviral therapy (ART) led to epidemiological changes in human immunodeficiency virus (HIV) associated lymphoma in high-income countries such as reductions in diffuse large B-cell lymphoma (DLBCL) and stable or increased Hodgkin lymphoma (HL) and Burkitt lymphoma (BL). In 2016, Malawi implemented a universal ART (UART) policy, expanding ART eligibility to all persons living with HIV (PLWH). We compare the distribution of lymphoma subtypes and baseline HIV and prognostic characteristics for lymphoma patients in Malawi before and after implementation of UART. We enrolled patients with pathologically confirmed incident lymphoproliferative disorders into a observational clinical cohort. At diagnosis, a comprehensive clinicopathological evaluation was performed. Of 412 participants, 156 (38%) were pre-UART (2013-June 2016) and 256 (62%) post-UART (July 2016-2020). HIV prevalence was 50% in both groups. The most common pre-UART diagnoses were DLBCL [75 (48%)], low-grade non-Hodgkin lymphoma (NHL) [19 (12%)], HL [17 (11%)] and, BL [13 (8%)]. For post-UART they were DLBCL [111 (43%)], NHL [28 (11%)], BL [27 11%)] and, HL [20 (8%)]. Among PLWH, 44 (57%) pre-UART initiated ART prior to lymphoma diagnosis compared to 99 (78%) post-UART (p = 0.02). HIV-ribonucleic acid was suppressed <1000 copies/mL in 56% (33/59) pre-UART and 71% (73/103) post-UART (p = 0.05). CD4 T-cell counts were similar for both groups. We observed similar findings in the subset of participants with DLBCL. Overall, there were no significant changes in incident lymphoma subtypes (p = 0.61) after implementation of UART, but HIV was better controlled. Emerging trends bear monitoring and may have implications for prognosis and health system priority setting. Trial registration: ClinicalTrials.gov identifier: NCT02835911.

PubMed Disclaimer

Conflict of interest statement

No commercial support was provided for this study. This work was completed while Dr. Satish Gopal was employed at the University of North Carolina at Chapel Hill. The opinions expressed in this article are the authors own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States Government.

Figures

Fig 1
Fig 1. Distribution of lymphoma subtypes by HIV status in the pre-universal ART and post-universal ART period.
Shown are absolute number of cases on the x-axis and percentage for the time period on the bar graph labels. *HIV status missing for one participant in post-UART. Abbreviations: pre-universal ART (pre-UART); post-universal ART (post-UART); Diffuse large B-cell lymphoma (DLBCL); low-grade non-Hodgkin’s lymphoma (LGNHL); T-cell non-Hodgkin’s lymphoma (T-Cell NHL); acute lymphoblastic leukemia/lymphoma (ALL); primary effusion lymphoma (PEL).

Similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424. - PubMed
    1. Mwamba PM, Mwanda WO, Busakhala NW, Strother RM, Loehrer PJ, Remick SC. AIDS-Related Non-Hodgkin’s Lymphoma in Sub-Saharan Africa: Current Status and Realities of Therapeutic Approach. Lymphoma. 2012;2012:1–9. doi: 10.1155/2012/904367 - DOI - PMC - PubMed
    1. Sylla BS, Wild CP. A million africans a year dying from cancer by 2030: What can cancer research and control offer to the continent? Vol. 130, International Journal of Cancer. 2012. p. 245–50. doi: 10.1002/ijc.26333 - DOI - PMC - PubMed
    1. Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, et al.. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013;105(16):1221–9. doi: 10.1093/jnci/djt158 - DOI - PMC - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015;136(5):E359–86. doi: 10.1002/ijc.29210 - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data